Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase.

The Cambridge based biotech company has successfully completed its Series A raise of £15m, with funding from industry veterans, institutional venture and strategic investors.

SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Their first investigational product, Aurase, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.

Speaking upon the completion of the round, Dr Sam Bakri, Founder and CEO of SolasCure said: “We are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development.  We are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.”

The raise began with investment from BRAIN Biotech AG (Xetra:BNN), who are SolasCure’s largest shareholder.

Adriaan Moelker, CEO BRAIN Biotech AG, said: “It has been an encouraging sign for all partners that SolasCure has been able to successfully close another financing round with rising pre-money valuation during the pandemic. We continue to be committed to support SolasCure on its way to market for the innovative wound debridement enzyme Aurase.